Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 11/20 | 0.46 |
| ▸ | PNMT | P11086 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24496339 | 1.00 | IDH2 (0.46) | IDH2PNMTALDH1A1CA12CA1 | |
| SCHEMBL20155326 | 0.81 | ALDH1A1 (0.59) | PNMTALDH1A1CA1CA2CA9 | |
| SCHEMBL10290708 | 0.80 | PNMT (0.45) | IDH2PNMTALDH1A1CA12CA1 | |
| SCHEMBL25277539 | 0.79 | CYP3A4 (0.56) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL3013616 | 0.78 | CA1 (0.51) | PNMTALDH1A1CA12CA1CA2 | |
| SCHEMBL29648426 | 0.78 | ALDH1A1 (0.56) | ALDH1A1 | |
| SCHEMBL24496279 | 0.78 | ALDH1A1 (0.56) | ALDH1A1 | |
| SCHEMBL15647830 | 0.78 | VCAM1 (0.58) | IDH2PNMTALDH1A1 | |
| SCHEMBL2542954 | 0.78 | IDH2 (0.52) | IDH2PNMT | |
| SCHEMBL15646664 | 0.77 | VCAM1 (0.47) | PNMTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022120353-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |